Cidara Therapeutics Inc (CDTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cidara Therapeutics Inc (CDTX) has a cash flow conversion efficiency ratio of -0.096x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.62 Million) by net assets ($422.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cidara Therapeutics Inc (CDTX) balance sheet quality index to measure how much of total assets are equity-financed.
Cidara Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Cidara Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CDTX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Cidara Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cidara Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
New Gold Inc
TO:NGD
|
0.175x |
|
Huadian Power International Corp Ltd Class A
SHG:600027
|
0.042x |
|
GPT Group
AU:GPT
|
0.035x |
|
CAR Group Ltd
AU:CAR
|
0.079x |
|
RATIONAL UN.ADR 1/ 1/20
F:RAA1
|
0.096x |
|
Definity Financial Corp
TO:DFY
|
-0.030x |
|
Changjiang Securities Co Ltd
SHE:000783
|
0.314x |
|
National Aluminium Company Limited
NSE:NATIONALUM
|
0.126x |
Annual Cash Flow Conversion Efficiency for Cidara Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Cidara Therapeutics Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Cidara Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $163.31 Million | $-176.53 Million | -1.081x | -139.56% |
| 2023-12-31 | $-8.21 Million | $-22.43 Million | 2.732x | +38.55% |
| 2022-12-31 | $-14.44 Million | $-28.47 Million | 1.972x | +268.61% |
| 2021-12-31 | $21.57 Million | $-25.23 Million | -1.170x | +76.97% |
| 2020-12-31 | $10.71 Million | $-54.41 Million | -5.078x | -573.37% |
| 2019-12-31 | $37.84 Million | $-28.53 Million | -0.754x | +21.35% |
| 2018-12-31 | $59.14 Million | $-56.70 Million | -0.959x | -14.78% |
| 2017-12-31 | $59.74 Million | $-49.91 Million | -0.835x | -85.22% |
| 2016-12-31 | $88.18 Million | $-39.77 Million | -0.451x | -80.54% |
| 2015-12-31 | $103.91 Million | $-25.96 Million | -0.250x | +31.62% |
| 2014-12-31 | $21.10 Million | $-7.71 Million | -0.365x | -148.74% |
| 2013-12-31 | $-1.40 Million | $-1.05 Million | 0.750x | -- |
About Cidara Therapeutics Inc
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are funga… Read more